Original scientific paper

https://doi.org/10.20471/acc.2021.60.03.06

Factors Affecting Outcome in the Treatment of Glioblastoma

Nenad Koruga orcid.org/0000-0001-7555-1155 ; Department of Neurosurgery, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Tatjana Pekmezović ; Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Ilijan Tomaš ; Department of Oncology, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Anamarija Soldo Koruga ; Department of Neurology, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Silva Butković Soldo ; Department of Neurology, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Zvonimir Užarević ; Department of Natural Sciences, Faculty of Education, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Krešimir Rotim ; Department of Neurosurgery, Sestre milosrdnice University Hospital Centre, School of Medicine, University of Zagreb, Zagreb, Croatia

Abstract

Treatment of glioblastoma is challenging due to its aggressive and highly invasive
nature, and no significant advances in survival have been achieved recently. The aim of our retrospective
study was identification of predictive factors and consequent survival outcome in patients who
underwent surgical and oncologic treatment of glioblastoma. The study was conducted at the Department
of Neurosurgery, Osijek University Hospital Centre. The authors designed a retrospective cohort
study in 63 patients who underwent surgical and oncologic treatment between January 1, 2012 and
December 31, 2017. Data were collected by reviewing medical records of the patients with histologically
proven glioblastoma. Statistical analysis of study results revealed a significant impact of postoperative
radiotherapy (p=0.002) and chemotherapy (p=0.016) on progression-free survival and overall
survival (p=0.001 and p=0.009, respectively). Postoperative Karnofsky performance scale (p=0.027)
was found to be significant in progression-free survival, and so was the interval between surgery and
commencement of oncologic therapy (p=0.049). In conclusion, overall survival and prognosis in the
treatment of glioblastoma remain poor, although prompt approach in postoperative adjuvant treatments
improved progression-free survival.

Keywords

Brain neoplasms; Glioblastoma; Radiotherapy; Temozolomide; Procarbazine

Hrčak ID:

271332

URI

https://hrcak.srce.hr/271332

Publication date:

1.9.2021.

Article data in other languages: croatian

Visits: 2.105 *